timothy sykes logo
SYRE Stock Jumps As Stifel Hikes Price Target To $92 Thumbnail
ADD US ONG Google News

SYRE Stock Jumps As Stifel Hikes Price Target To $92

JACK KELLOGG•UPDATED APR. 13, 2026, 5:04 PM ET
Reviewed by Tim Sykes Fact-checked by Ellis Hobbs

Spyre Therapeutics Inc. stocks have been trading up by 20.88 percent on strong optimism surrounding its latest clinical developments.

Candlestick Chart

Live Update At 17:03:54 EDT: On Monday, April 13, 2026 Spyre Therapeutics Inc. stock [NASDAQ: SYRE] is trending up by 20.88%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

SYRE has been trading like a biotech momentum name, not a sleepy pharma. Over the last few weeks, Spyre Therapeutics Inc. ran from the low‑$40s to a recent close of $63.27, with an intraday spike to $75 on 2026/04/13. That’s a huge percentage move in a short window, and traders need to respect that volatility.

On the daily chart, SYRE shows a clean uptrend: higher lows from about $41 on 2026/03/20 to the mid‑$60s now. Pullbacks into the high‑$40s and low‑$50s have been bought, confirming strong dip demand. Intraday, the 5‑minute tape on 2026/04/13 shows early strength, a wild morning range between $59.02 and $75, then tight consolidation in the low‑$60s into the close. That kind of range expansion often signals big event‑driven interest.

Fundamentally, SYRE is still a classic clinical‑stage biotech: no real revenue, a recent quarterly net loss of about $62.5M, and negative earnings per share of roughly -$0.74. Cash and short‑term investments are sizable at about $756.5M, backed by a strong current ratio of 13.3 and no long‑term debt. For traders, that means Spyre Therapeutics Inc. has runway to fund trials, but the stock’s direction is driven by data, not earnings.

Why Traders Are Watching SYRE Right Now

SYRE has quickly become one of those names every active biotech trader has on watch. The catalyst stack is dense, the price action is explosive, and Wall Street just raised the bar. When Stifel took its Spyre Therapeutics Inc. price target up from $70 to $92 and reaffirmed a Buy, it confirmed what the chart was already hinting at: expectations are climbing into the next data readouts.

The core of the story is SYRE’s TL1A‑targeted pipeline in inflammatory bowel disease and rheumatic conditions. Completion of enrollment ahead of schedule in the rheumatoid arthritis sub‑study of the SKYWAY Phase 2 basket trial is a serious execution win. It pulls week‑12 topline data into Q3 2026, shrinking the waiting period and tightening the feedback loop for traders who are betting on whether SYRE’s RA and broader rheumatic programs can add value beyond ulcerative colitis.

The market already reacted. After Spyre Therapeutics Inc. disclosed the SKYWAY progress, SYRE popped more than 6%, showing how sensitive the stock is to any clinical milestone. On top of RA, enrollment in psoriatic arthritis and axial spondyloarthritis arms is on track for Q4 2026 data, while the SKYLINE ulcerative colitis platform trial is enrolling ahead of plan with first Part A data expected in Q2 2026. That gives traders multiple “shots on goal” over the next few quarters.

Near term, the big magnet is 2026/04/13. Spyre Therapeutics Inc. plans to release Part A induction topline results from SKYLINE’s SPY001 in moderate‑to‑severe ulcerative colitis that day, followed by a webcast. This outcome will heavily influence how the Street views SYRE’s entire TL1A strategy. Positive data could keep momentum hot; weak data would hit a stock that has already run hard. Around the edges, the company has granted options to new employees and filed routine Form 4s on insider ownership shifts, but the real driver remains the clinical tape.

More Breaking News

Conclusion

For traders, SYRE is the textbook definition of an event‑driven biotech: strong balance sheet, heavy cash burn, and a stock price that lives and dies on trial readouts. Spyre Therapeutics Inc. has laid out a clear roadmap – SKYLINE ulcerative colitis data on 2026/04/13, followed by a wave of SKYWAY rheumatology readouts through Q3 and Q4 2026. Stifel’s price‑target hike to $92 simply underscores how much is now riding on those numbers.

The recent surge from the low‑$40s to the $60s shows that traders are already positioning ahead of these catalysts. When a name like SYRE starts putting in higher lows and breaking to new highs on clinical headlines, it attracts momentum players, algos, and short‑term swing traders all at once. That’s when the moves get fast, both directions.

The financials tell you SYRE is not a steady compounding story; it is a high‑risk, high‑reward biotech trade. Losses are large, returns on capital are deeply negative, and the valuation rests on future potential in TL1A‑targeted therapies. As Tim Sykes likes to remind traders, “The market doesn’t care about your opinion, only about price action and catalysts.” As millionaire penny stock trader and teacher Tim Sykes, says, “The goal is not to win every trade but to protect your capital and keep moving forward.”. With Spyre Therapeutics Inc., those catalysts are now on the calendar, and traders should treat every data date as a potential volatility spike — not a guarantee of profit.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading SYRE

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”